Quantum Computing Firm Quantinuum Raises $1.68bn in Heavily Oversubscribed Nasdaq IPO at $60 Per Share
Quantinuum (Nasdaq: QNT) raised $1.68 billion through its initial public offering on the Nasdaq Global Select Market, pricing at $60 per share — above the initial range — after underwriters expanded the offering to 28 million Class A shares. Shares opened at $68 on the first day of trading, a 13% premium to the IPO price, before closing little changed and giving the company a market value of approximately $15.7 billion. Founded in 2021 through a merger of Honeywell's quantum computing division and UK-based Cambridge Quantum, Quantinuum describes itself as a full-stack quantum computing platform covering both hardware and software. The UK connection is significant: Cambridge Quantum brought deep expertise in quantum software, algorithms, and cybersecurity, and the combined entity retains operations in Cambridge. The IPO was heavily oversubscribed, prompting underwriters to raise both the share count and price range before final pricing. The company generated $30.9 million in revenue in 2025 while posting a net loss of $192.6 million, meaning the $15.7 billion valuation is driven entirely by the market's assessment of future commercial potential for quantum computing rather than current earnings. The deal reflects sustained investor appetite for deep-technology listings, even at loss-making valuations, and marks the first major quantum computing IPO on a US exchange involving a UK-founded constituent business.
Why this matters
This is a consequential capital markets event for the quantum computing sector, generating work across IPO counsel, verification, and post-listing compliance. The UK nexus via Cambridge Quantum means English-law practices are relevant to the corporate history, even if the listing itself is on Nasdaq. The heavily oversubscribed book and premium opening trade confirm strong institutional demand for quantum computing equity. The wide gap between valuation ($15.7bn) and revenue ($30.9m) will sharpen scrutiny of the prospectus disclosure quality — particularly risk factors around commercialisation timelines — and may attract securities litigation if the share price corrects sharply.
On the Ground
A trainee on the IPO team would assist with prospectus drafting and proofreading, preparing verification notes to source-check every material claim in the document, and coordinating comfort letter requests from auditors. Post-listing, PDMR (person discharging managerial responsibilities) notification letters for insider trades and pricing supplement filings would also fall to junior lawyers.
Interview prep
Question you might get
“What key risk factors would you expect to see disclosed in the Quantinuum prospectus, and what legal exposure arises if those risks materialise post-listing?”
Sign up free to see the full answer
A model answer you can lift into an interview — how to frame this story for a partner.
Sign up freeMy notes
saved